Dominick Angiolillo, MD, PhD, on the TWILIGHT Trial Analysis of High-Risk Patients With Diabetes

In this podcast, Dominick J. Angiolillo, MD, PhD, provides insight into a new analysis of the TWILIGHT trial that he and his colleagues performed among high-risk patients with diabetes. It was a topic he discussed during ACC.20/WCC Virtual, when he presented the session, “Ticagrelor With and Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: Insights From the TWILIGHT Trial.”

Additional Resources:

• Angiolillo DJ, Baber U, Sartori S, et al. Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention [published online March 30, 2020]. J Am Coll Cardiol. doi:10.1016/j.jacc.2020.03.008
• Angiolillo DJ. Ticagrelor with and without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention: insights from the TWILIGHT trial. Paper presented at: the American College of Cardiology Virtual Annual Scientific Session Together With World Congress of Cardiology; March 28-30, 2020; virtual. https://acc.mediasite.com/mediasite/play/b6c8a7c6fdd64b6597c8e19255c5c9ce1d?autoStart=true. Accessed April 20, 2020.
• Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381:2032-2042. doi:10.1056/NEJMoa1908419

Dominick J. Angiolillo, MD, PhD, is a professor in the Department of Medicine, Division of Cardiology, at the University of Florida College of Medicine — Jacksonville. There, he also serves as the medical director of the Cardiovascular Research Program, the program director of the Interventional Cardiology Fellowship Program, and the associate program director of the Cardiovascular Disease Fellowship.